Summary Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral entry protein, spike. Because new SARS-CoV-2 variants are emerging rapidly, as exemplified by the B.1.1.7, B.1.351, and P.1 lineages, it is critical to understand whether antibody responses induced by infection with the original SARS-CoV-2 virus or current vaccines remain effective. In this study, we evaluate neutralization of a series of mutated spike pseudotypes based on divergence from SARS-CoV and then compare neutralization of the B.1.1.7 spike pseudotype and individual mutations. Spike-specific monoclonal antibody neutralization is reduced dramatically; in contrast, polyclonal antibodies from individuals infected in early 2020 remain active against most mutated spike pseudotypes, but potency is reduced in a minority of samples. This work highlights that changes in SARS-CoV-2 spike can alter neutralization sensitivity and underlines the need for effective real-time monitoring of emerging mutations and their effect on vaccine efficacy. Graphical abstract Highlights • SARS-CoV-2 pseudotypes produced by amino acids substitutions in SARS-CoV • SARS-CoV-2 pseudotyped virus that encodes the B.1.1.7 variant spike • Amino acid changes and B.1.1.7 can decrease monoclonal antibody neutralization • Minimal effect on sera with only 10% losing potency against the B.1.1.7 pseudotype This study describes neutralization by antibodies and convalescent sera of SARS-CoV-2 spike mutants. Rees-Spear et al. show that SARS-CoV amino acid substitutions and the B.1.1.7 variant can block monoclonal antibody neutralization and that serum samples collected following mild illness are less resilient to spike variation than those following severe illness.
【저자키워드】 antibodies, SARS-CoV-2, serology, neutralization, variant, Immune escape, B.1.1.7, 【초록키워드】 neutralizing antibody, Efficacy, Vaccine, coronavirus, Mutation, Neutralizing antibodies, antibody, SARS-CoV, B.1.351, neutralization, Antibody Response, monoclonal antibody, Variation, mutations, vaccine efficacy, Infection, SARS-CoV-2 virus, severe acute respiratory syndrome Coronavirus, viral entry, Protein, sensitivity, Antibody responses, B.1.1.7 variant, Viral, SARS-CoV-2 variants, Pseudotyped virus, B.1.1.7, pseudotype, P.1, sera, amino acids, mutants, polyclonal antibodies, respiratory, lineages, change, Critical, convalescent sera, Protective, SARS-CoV-2 spike, Amino acid, amino acid changes, polyclonal antibody, acute respiratory syndrome, Real-time monitoring, Abstract, Divergence, acute respiratory syndrome coronavirus, serum samples, individual, potency, Substitution, mild illness, SARS-CoV-2 pseudotyped virus, Multiple, ENCODE, serum sample, amino acid substitution, Alter, effective, decrease, variant spike, highlight, new SARS-CoV-2, produced, collected, evaluate, reduced, less, changes in, active against, mutated, recognizing, 【제목키워드】 spike mutation, SARS-CoV-2 neutralization,